such as p53–MDM2 and NF-κB. The two areas that are most likely to produce approved products in the near future are agents that promote apoptosis via the BCL-2 family of regulatory proteins ...
It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback